{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T23:31:29Z","timestamp":1698276689971},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":6241,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1989,6,15]]},"abstract":"Abstract<\/jats:title>Non\u2010Hodgkin lymphoma (NHL) patients with centroblastic (Cb) or centroblastic\u2010centrocytic (Cb\/Cc)\u2010diffuse lymphomas, immunocytoma (IC) and chronic lymphocytic leukemia (CLL) in clinical stages III\u2010IV and with active disease (highly malignant group) were compared to NHL patients with CLL, IC, and centrocytic (Cc) or centroblastic\u2010centrocytic (Cb\u2010Cc)\u2010diffuse\/follicular lymphomas, in clinical stages I\u2010II and with inactive disease (low malignant group) based on the presence of antibodies to Epstein\u2010Barr virus (EBV) nuclear antigen I (EBNA\u2010I) and 2 (EBNA\u20102). In the highly malignant group, anti\u2010EBNA\u20101 geometric mean titers (GMT) were 13.2 (range <2\u201080) and anti\u2010EBNA\u20102 60.6 (range: 20\u2010320). The ratio between the logarithms of anti\u2010EBNA\u20101 and anti\u2010EBNA\u20102 antibody titers was <1.0 (mean: 0.32) in all the patients examined. In 6 out of 8 patients of the low malignant group, anti\u2010EBNA\u2010I titers were higher (mean: 30.1; range 10\u2010160) than anti\u2010EBNA\u20102 titers (mean: 4.3; range <2\u201080) and the EBNA 1\/2 ratio was >1.0. In healthy EBV\u2010seropositive individuals, anti\u2010EBNA\u2010I GMT were 49 (range: 10\u2010320) and only 5 out of 17 individuals had detectable anti\u2010EBNA\u20102 titers (GMT: 3; range <5\u201020). The EBNA\u20101\/2 ratio was in all cases >1. Among patients of the highly and low malignant groups, patients with follicular\u2010cell\u2010derived lymphomas had elevated antibody titers against the restricted component of early antigens (EAR), whereas all patients with IC and 2 out of 4 CLL patients had elevated antibody titers against the diffuse component of early antigens (EA\u2010D). The results indicate that the ratio between anti\u2010EBNA\u20101 and anti\u2010EBNA\u20102 antibody titers may be of diagnostic importance in patients with immunodeficiencies.<\/jats:p>","DOI":"10.1002\/ijc.2910430610","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T21:45:23Z","timestamp":1171921523000},"page":"1017-1021","source":"Crossref","is-referenced-by-count":5,"title":["Relationship between clinical stage, histopathology and antibody titers against the second epstein\u2010barr virus nuclear antigen (EBNA\u20102) in non\u2010Hodgkin's lymphoma patients"],"prefix":"10.1002","volume":"43","author":[{"given":"G.","family":"Masucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Henle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Henle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rymo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ernberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.17.6641"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910370205"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1985.tb03855.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910420305"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/130.3.231"},{"key":"e_1_2_1_7_1","first-page":"4222","article-title":"Epstein\u2010Barr virus\u2010Specific serology in immunologically compromised individuals","volume":"41","author":"Henle W.","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.2.570"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican0779-48"},{"key":"e_1_2_1_10_1","first-page":"237","volume-title":"Oncogenesis and herpes viruses","author":"Johansson B.","year":"1975"},{"key":"e_1_2_1_11_1","volume-title":"Handbuch des speziellen pathologischen Anatomie und Histologie","author":"Lennert K.","year":"1978"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910320605"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90373-7"},{"key":"e_1_2_1_14_1","first-page":"1288","article-title":"Immunological characterization of Hodgkin's lymphoma patient with high antibody titer against Epstein\u2010Barr virus\u2010Associated antigens","volume":"44","author":"Masucci G.","year":"1984","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","first-page":"4292","article-title":"Cell\u2010Mediated immune reaction in three patients with malignant lymphoproliferative diseases in remission and abnormally high Epstein\u2010Barr antibody titers","volume":"41","author":"Masucci M. G.","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/156.1.26"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910110302"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02568.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.10.3435"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910400311"},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","unstructured":"Szigeti R. Kallin B. Dillner J. Henle G. Henle W. Lerner R. Rymo L. Timar L.andKlein G. Epstein\u2010Barr virus (eBV) antigen specific leukocyte migration inhibition (lMI) in infectious mononucleosis (iM): II. Kinetics of sensitization against the 6 EBV\u2010Encoded nuclear proteins (eBNA\u20106) and the latent membrane protein (lMP).Clin. Immunol. Immunopath.(1989) (in press).","DOI":"10.1016\/0090-1229(89)90037-8"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910400318"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910430610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910430610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T11:13:12Z","timestamp":1697973192000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910430610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,6,15]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1989,6,15]]}},"alternative-id":["10.1002\/ijc.2910430610"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910430610","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,6,15]]}}}